Recent studies highlight that FOXM1 inhibitors, when combined with anti-VEGFR2 agents, enhance angiogenesis suppression in HCC xenografts [32], mirroring the dual targeting observed for HO-1197. Here, FOXM1 is linked to hepatocellular carcinoma.